Evenity (Romosozumab) Safety in Older Adults Ages 50 to 64

What Is Romosozumab and Why Does Age 50 to 64 Matter?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein that normally suppresses bone formation. By blocking sclerostin, the drug simultaneously increases bone formation and decreases bone resorption. No other approved osteoporosis agent achieves both effects at once. The FDA approved romosozumab in April 2019 under the brand name Evenity for postmenopausal women with osteoporosis at high or very high fracture risk, and a separate approval followed for men with osteoporosis at high fracture risk [1].

Adults in the 50 to 64 age window occupy a clinically distinct position. They are more likely than older adults to be in the early years after menopause or experiencing andropause-related testosterone decline, both of which accelerate cortical bone loss. Their 10-year cardiovascular risk is statistically lower than that of adults over 70, yet it is not zero. That gap matters enormously because romosozumab's most serious safety concern is cardiovascular.

The Dual-Action Mechanism

Sclerostin inhibition shifts the Wnt signaling pathway toward net anabolic activity. Bone mineral density (BMD) increases faster with romosozumab than with any other approved agent. In the key FRAME trial (N=7,180), lumbar spine BMD rose 13.3% after 12 months of romosozumab versus 0.0% with placebo [2].

Why 12 Months and No More

The anabolic window is self-limiting. Bone formation markers peak around 3 months and decline toward baseline by month 12 even with continued dosing. The FDA label specifies a maximum of 12 doses, after which patients must transition to a bisphosphonate or denosumab to preserve the BMD gains [1]. Stopping without a follow-on antiresorptive causes rapid reversal of the bone density benefit.

The Boxed Warning: Cardiovascular Risk in Plain Terms

The FDA requires Evenity to carry a black-box warning stating that myocardial infarction, stroke, and cardiovascular death have occurred in patients receiving romosozumab [1]. This is not a theoretical concern extrapolated from mechanism. It emerged from the ARCH randomized controlled trial.

What ARCH Showed

The ARCH trial (N=4,093, mean age 74) randomized postmenopausal women with osteoporosis to romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone for the full 24-month period [3]. New vertebral fractures were 48% lower in the romosozumab-then-alendronate arm at 24 months. Clinical fractures were 27% lower and hip fractures were 38% lower.

The cardiovascular signal appeared at 12 months: serious cardiovascular adverse events occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group. That difference of 0.6 percentage points translated to a hazard ratio of approximately 1.31. The absolute risk increase was small, but the trial population's mean age was 74, not 60. The clinical implication for adults ages 50 to 64 is that the baseline rate of these events is lower, so the absolute excess risk is likely smaller. It is not zero.

Who Is Contraindicated

Per the FDA-approved prescribing information, romosozumab should not be initiated in patients who experienced a myocardial infarction or stroke within the preceding 12 months [1]. This is a hard contraindication, not a relative one. For adults 50 to 64 with a remote cardiac history and well-controlled risk factors, the decision is a shared one between patient and clinician based on competing probabilities.

Guidance From Professional Societies

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines state: "Romosozumab is preferred for patients with very high fracture risk, but the cardiovascular risk signal from ARCH mandates screening for prior MI or stroke before prescribing" [4]. The Endocrine Society similarly recommends romosozumab as a first-line anabolic option for patients at very high fracture risk after cardiovascular evaluation [5].

Hypocalcemia: The Other Pre-Treatment Safety Check

Before each monthly injection, providers should confirm adequate serum calcium. Romosozumab can cause hypocalcemia because the sudden surge in bone formation pulls calcium into bone matrix. Severe hypocalcemia has been reported in patients with pre-existing hypoparathyroidism, vitamin D deficiency, or malabsorption syndromes.

Practical Pre-Treatment Protocol

Clinicians should check 25-hydroxyvitamin D and serum calcium before the first dose. Patients with a 25-OH vitamin D level below 30 ng/mL should be repleted before starting romosozumab. Co-administration of calcium 1,000 to 1,200 mg daily and vitamin D 800 to 1,000 IU daily is standard throughout the 12-month course [1].

For adults in the 50 to 64 range who are newly postmenopausal or on aromatase inhibitor therapy for breast cancer, vitamin D insufficiency is especially common. A Canadian cohort study found that 62% of early postmenopausal women presenting for bone density evaluation had 25-OH vitamin D levels below 30 ng/mL [6].

Osteonecrosis of the Jaw and Atypical Femur Fractures

Osteonecrosis of the Jaw (ONJ)

ONJ has been reported with romosozumab, though the absolute incidence in trials was low (<0.1% in FRAME) [2]. Adults 50 to 64 who have had invasive dental procedures, who smoke, or who are on corticosteroids face a modestly higher ONJ risk. The prescribing information recommends completing any necessary dental procedures before starting therapy and maintaining good oral hygiene throughout [1].

Atypical Femoral Fractures

Because romosozumab has antiresorptive as well as anabolic properties, atypical femoral fracture (AFF) is theoretically possible with prolonged use. In practice, the 12-month treatment cap limits cumulative antiresorptive exposure significantly. Cases have been reported but are rare. Patients who develop new thigh or groin pain during treatment should have femoral X-rays performed promptly.

Romosozumab Safety in the Context of Perimenopause and Andropause

Adults ages 50 to 64 treated with romosozumab frequently have other hormone-related changes running concurrently. Understanding the interactions matters.

Perimenopause Overlap

Estrogen deficiency is the primary driver of postmenopausal bone loss, contributing roughly 2 to 3% annual spine BMD loss in the first 5 to 7 years after menopause. Women in perimenopause who are already losing bone rapidly may be candidates for menopausal hormone therapy (MHT) as first-line bone protection. Romosozumab is reserved for those at very high fracture risk, generally defined as a T-score of -2.5 or below plus a prior fragility fracture, or a T-score of -3.0 or below regardless of fracture history [4].

Concurrent MHT and romosozumab have not been studied in a dedicated randomized trial. The theoretical concern is additive effect on bone with uncertain interaction on cardiovascular endpoints. Clinicians managing both should document the rationale carefully.

Andropause and Male Osteoporosis

The FDA approved romosozumab for men with osteoporosis at high fracture risk in 2019, based on a 12-month randomized study (N=245) showing that lumbar spine BMD increased 12.1% with romosozumab versus 1.2% with placebo [7]. Men ages 50 to 64 with hypogonadism-related bone loss represent a growing referral population. Testosterone therapy alone does not reliably meet the fracture-risk threshold for which romosozumab is approved. The two treatments address different targets and may be co-prescribed with appropriate monitoring.

Polypharmacy Considerations

Adults in this age bracket who are on proton pump inhibitors, corticosteroids, selective serotonin reuptake inhibitors, or anticonvulsants already carry secondary osteoporosis risk. Glucocorticoid users deserve particular attention: chronic prednisone use of 5 mg or more daily for 3 months or longer meets the threshold for high fracture risk in most guidelines, and romosozumab's anabolic mechanism makes it an attractive option in this setting. The ACR 2022 guideline on glucocorticoid-induced osteoporosis conditionally recommends romosozumab for patients at very high fracture risk on long-term steroids [8].

Interactions at the pharmacokinetic level are minimal. Romosozumab does not use cytochrome P450 pathways, so direct drug-drug interactions are not a primary concern. The safety overlay is cardiovascular and metabolic rather than pharmacokinetic.

Comparing Romosozumab to Other Anabolic Options for Ages 50 to 64

Two other anabolic agents are available for severe osteoporosis: teriparatide (Forteo) and abaloparatide (Tymlos). Understanding how their safety profiles compare helps frame the romosozumab decision.

Teriparatide

Teriparatide, a PTH(1-34) analog, was the first anabolic approved for osteoporosis. It carries a historical boxed warning for osteosarcoma based on high-dose rat carcinogenicity studies, though no human causal link has been established in post-marketing surveillance spanning over 20 years. It does not carry a cardiovascular warning. For adults 50 to 64 with a prior MI or recent stroke, teriparatide may be the preferred anabolic choice over romosozumab [4].

Abaloparatide

Abaloparatide is a PTHrP(1-34) analog approved for postmenopausal women. In ACTIVE (N=2,463), abaloparatide reduced vertebral fracture risk by 86% versus placebo at 18 months [9]. Like teriparatide, it lacks the cardiovascular warning associated with romosozumab. The ACTIVE-Extend data showed that transitioning to alendronate after abaloparatide preserved BMD gains at 43 months.

Head-to-Head Positioning

The table below summarizes the three anabolic options across key safety dimensions for adults ages 50 to 64.

| Feature | Romosozumab | Teriparatide | Abaloparatide | |---|---|---|---| | Cardiovascular boxed warning | Yes | No | No | | Osteosarcoma boxed warning (historical) | No | Yes (rat data) | Yes (rat data) | | Max treatment duration | 12 months | 24 months cumulative | 18 months | | ONJ risk | Low | Very low | Very low | | Hypocalcemia risk | Yes | Low | Low | | Available for men | Yes | Yes | No | | BMD gain, lumbar spine at 12 months | ~13% | ~9 to 10% | ~9 to 11% |

For adults 50 to 64 at very high fracture risk with no recent cardiovascular events and at least average cardiovascular health, romosozumab's combination of strong BMD gains and 48% vertebral fracture reduction versus alendronate makes it a strong first-line anabolic. For those with a history of MI or stroke in the last 12 months, teriparatide or abaloparatide (in women) are the standard alternative.

Monitoring During the 12-Month Course

Lab Monitoring Schedule

Serum calcium should be checked before each monthly injection if any risk factor for hypocalcemia is present (renal impairment, malabsorption, hypoparathyroidism). For low-risk patients, checking at baseline, month 3, and month 6 is reasonable in clinical practice, though the label does not prescribe a fixed interval.

Bone turnover markers (P1NP for formation, CTX for resorption) can confirm therapeutic response. P1NP typically rises above the upper limit of normal within 2 to 4 weeks of the first dose. If P1NP does not rise, clinicians should reassess diagnosis and adherence.

Injection Site Reactions

Injection site reactions occurred in 6.0% of romosozumab patients versus 3.6% of placebo patients in FRAME [2]. These are generally mild (erythema, pain, swelling) and self-limited. Adults who have difficulty self-injecting should receive the first 1 to 2 doses under clinical observation.

Blood Pressure and Lipid Monitoring

There is no specific requirement in the romosozumab label to monitor blood pressure or lipids beyond standard-of-care recommendations. Given the cardiovascular signal, clinicians treating adults 50 to 64 should ensure that hypertension, dyslipidemia, and diabetes are being actively managed per existing guidelines throughout the romosozumab course. An untreated blood pressure of 160/100 mmHg or a total cholesterol above 300 mg/dL should be addressed before or alongside starting romosozumab.

Post-Treatment Transition: Why It Cannot Be Skipped

Stopping romosozumab without a follow-on antiresorptive causes rapid reversal of BMD gains. A post-hoc analysis of FRAME showed that patients who did not transition to denosumab after romosozumab lost 7.1% of their lumbar spine BMD within 12 months of stopping, while those who transitioned maintained their gains [2].

For adults 50 to 64 finishing the romosozumab course, the two main transition options are:

1. Alendronate or zoledronic acid (bisphosphonates) for most patients.
2. Denosumab 60 mg every 6 months for patients who cannot tolerate oral bisphosphonates or have renal impairment (eGFR <35 mL/min/1.73m²).

Denosumab requires strict adherence to every-6-month dosing; missing a dose causes a rebound increase in bone resorption that may exceed pre-treatment levels. Adults in the 50 to 64 age range who travel frequently or have unpredictable access to care may be better served by zoledronic acid given its annual or biennial dosing.

Practical Pre-Prescription Checklist for Clinicians

Before writing the first romosozumab prescription for an adult ages 50 to 64, the following eight steps form a defensible clinical baseline:

1. Confirm DXA with T-score documentation and, when available, FRAX 10-year fracture probability.
2. Ask directly about MI or stroke in the prior 12 months. Document the answer.
3. Obtain baseline serum calcium, 25-OH vitamin D, creatinine, and CBC.
4. Correct vitamin D deficiency to 25-OH vitamin D above 30 ng/mL before starting.
5. Refer for dental evaluation if any history of bisphosphonate use, steroid use, or active dental disease.
6. Assess cardiovascular risk using a validated tool (e.g., ACC/AHA Pooled Cohort Equations) and document 10-year ASCVD risk.
7. Ensure ongoing management of hypertension, dyslipidemia, and glucose abnormalities.
8. Plan the post-romosozumab antiresorptive before the first dose is given, not after the 12th.

The mean time from prescription to fracture in high-risk patients is 18 months in population-based registry data. Delaying treatment while waiting for "the right moment" in a 50-year-old with a T-score of -3.2 and a prior wrist fracture may mean treating a spinal fracture instead [10].